glp-1 drug novo nordisk launches Wegovy weight-loss pill in US, triggering price war | Pharmaceuticals industry 80% of Wegovy Pill Users

By balancing the potential benefits and risks of treatment using evidence-based strategies, HCPs are well placed to help optimise the use of GLP-1 RAs in the management of obesity and overweight

While injectable GLP-1 medications generally have no direct pharmacokinetic interaction with levothyroxine, there are important considerations regarding oral semaglutide and indirect effects that warrant attention

For example, a 49-year-old woman with T2D accidentally injected the whole liraglutide pen and received a total dose of 18 mg [179]

Common side effects reported with semaglutide may include nausea, vomiting, diarrhea, and constipation